Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Clifton Smith

Procedural Dermatology Lexington, KY Medical Doctor

NPI 1114991296 CMS profile 95650

177 Burt Rd, Lexington, KY 40503

Open in the dashboard

General payments

$3,873

233 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Clifton Smith of Lexington, KY is reported in the CMS Open Payments database as having received $3,873 across 233 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $20 1
2021 General $861 54
2020 General $1,333 79
2019 General $1,660 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clifton Smith
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Clifton Smith were reported at $0. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Clifton Smith Procedural Dermatology median Middle half National median
2019 $1,660 $454 $152–$1,260 $163
2020 $1,333 $243 $90–$835 $114
2021 $861 $337 $102–$1,128 $132
2022 $20 $443 $119–$1,654 $149
2023 $0 $583 $137–$1,838 $160
2024 $0 $611 $132–$1,835 $164
2025 $0 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AbbVie, Inc. $848 64 payments
  2. Galderma Laboratories, L.P. $396 12 payments
  3. Novartis Pharmaceuticals Corporation $386 18 payments
  4. Genentech USA, Inc. $352 24 payments
  5. UCB, Inc. $264 15 payments
  6. Amgen Inc. $219 13 payments
  7. Sun Pharmaceutical Industries Inc. $216 10 payments
  8. Pfizer Inc. $160 11 payments
  9. Janssen Biotech, Inc. $133 10 payments
  10. Genzyme Corporation $126 7 payments
  11. Other $772 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,723 232 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $150 1 payment
Products named General payments · program years 2019–2022
  1. HUMIRA $725 46 payments
  2. SKYRIZI $603 49 payments
  3. Erivedge $352 24 payments
  4. Cimzia $264 15 payments
  5. COSENTYX $230 8 payments
  6. EUCRISA $160 11 payments
  7. Enbrel $147 9 payments
  8. TREMFYA $133 10 payments
  9. ILUMYA $133 6 payments
  10. STELARA $114 9 payments
  11. Other $1,992 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record